Back Other STDs

Other STDs

Chlamydia Widespread in U.S., Task Force Recommends Screening for Young Women

Chlamydia -- the most commonly reported sexually transmitted infection in the U.S. -- had an overall prevalence of 1.7% among people age 14 to 39 in the latest NHANES survey, but this rose to 4.7% among sexually active young women. Updated guidelines from the U.S. Preventive Services Task Force recommend regular chlamydia and gonorrhea screening for sexually active women age 24 and younger, and for older women at increased risk for infection, but state that there is not enough evidence to make a similar recommendation for men.

alt

Read more:

ICAAC 2014: Delafloxacin Shows Promise as a Single-dose Treatment for Gonorrhea

A new antibiotic, delafloxacin, demonstrated potent activity against gonorrhea -- including drug-resistant strains -- in a laboratory study, and its pharmacokinetics suggest that single-dose oral treatment will be feasible, according to research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

Read more:

Coalition Calls for Wider Use of Sexual Health Care Services in U.S.

The National Coalition for Sexual Health -- comprised of nearly 40 organizations focused on HIV, sexually transmitted diseases, and other aspects of sexual health -- last week issued a call-to-action and announced new resources aimed at improving access to and acceptance of sexual health services, which are now more readily available under the Affordable Care Act (ACA).

alt

Read more:

STD Prevention Conference: Drug-resistant Gonorrhea Rates Plummet in U.S.

Preliminary results announced at the U.S. 2014 STD Prevention Conference last week in Atlanta have shown that the proportion of cases of gonorrhea that are drug-resistant has fallen since 2011, with a sharp decline between 2012 and 2013. The fall is particularly marked among gay and other men who have sex with men (MSM), who had had the highest rates of drug-resistant gonorrhea.
alt

Read more:

Helicase Inhibitor Pritelivir Shows Promise Against Genital Herpes

Pritelivir, a helicase inhibitor that interferes with viral replication, reduced the rate of herpes simplex virus type 2 (HSV-2) genital shedding, which has the potential to reduce sexual transmission, according to a small study described in the January 16, 2014, New England Journal of Medicine.

alt

Read more: